Functional Neurological Disorder during Foscarbidopa/Foslevodopa Infusion in PRKN ‐Associated Parkinsonism
Year: 2026
Type: article
Study design: Case Report
Abstract: Ethical Compliance Statement: Institutional Review Board approval was not required for this work. Written informed consent was obtained directly from the patient for participation in this work and for publication of the clinical details. In the form, the patient has given consent for her clinical information, video, and images to be reported in the journal. The patient understands that names and initials will not be published and that due efforts will be made to conceal identity, but anonymity cannot be guaranteed. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. All study procedures were performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Funding Sources and Conflict of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the previous 12 months: ZY declares that there are no additional disclosures to report. NOChP declares that there are no additional disclosures to report. DPMP declares that there are no additional disclosures to report. BTdlE declares that there are no additional disclosures to report. MAK is an employee of the CONICET and has received grant support from the Ministry of Science and Technology of Argentina and the Ministry of Health of Buenos Aires. AJE has received grant support from the NIH and the Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acorda, Abbvie, Bial, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He cofounded REGAIN Therapeutics to fund preclinical studies but relinquished the right to any personal income from future treatments. LM has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society for social media and web support, and personal compensation as a consultant/scientific advisory board member for Acadia, ExpertConnect, and Mirum Pharmaceuticals. LM has received a grant (collaborative research agreement) from the International Parkinson and Movement Disorders Society for the MDS-UTRS Validation Program (Role: PI), Non-Profit. The data that support the findings of this study are available from the corresponding author upon reasonable request.
DOI: 10.1002/mdc3.70564
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7129048408